Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday, ValuEngine reports.
Separately, Goldman Sachs Group assumed coverage on shares of Hikma Pharmaceuticals in a research note on Tuesday, September 3rd. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $25.00.
Hikma Pharmaceuticals stock opened at $25.40 on Thursday. The firm has a market cap of $6.03 billion, a PE ratio of 18.41 and a beta of 0.15. The firm’s 50 day moving average price is $25.35 and its two-hundred day moving average price is $23.26. Hikma Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $26.65.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Recommended Story: What is the NASDAQ?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.